CT-95 in Advanced Cancers Associated With Mesothelin Expression
Conditions
Mesothelin-Expressing Tumors · Epithelial Ovarian Cancer · Malignant Pleural Mesothelioma, Advanced · Malignant Peritoneal Mesothelioma, Advanced · Pancreatic Adenocarcinoma Advanced or Metastatic · Lung Adenocarcinoma Metastatic · Cholangiocarcinoma Advanced · Cholangiocarcinoma Non-resectable · Mesothelin-expressing Advanced Cancers · Mesothelin-positive Advanced Malignant Solid Tumors · Colorectal Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Context Investigational Site, Denver, Colorado, United States
Context Investigational Site, Chicago, Illinois, United States
Contact: Study coordinator (Cancer Clinical Trials) · Cancerclinicaltrials@bsd.uchicago.edu · 773-702-6233Context Investigational Site, Grand Rapids, Michigan, United States
Context Investigational Site, Hackensack, New Jersey, United States
Contact: Study coordinator (Oncology Clinical Research Referral Office) · OncologyResearchReferral@hmhn.org · 551-996-1777University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Andrea Standish) · Andrea.Standish@Pennmedicine.upenn.edu · 215-662-2419Context Investigational Site, Philadelphia, Pennsylvania, United States
Context Investigational Site, Nashville, Tennessee, United States
Context Investigational Site, San Antonio, Texas, United States
Context Investigational Site, San Antonio, Texas, United States
Study leads
Karen Chagin, MD
Study Director
Context Therapeutics Inc.